Filtered By:
Condition: Atrial Fibrillation
Management: Insurance

This page shows you your search results in order of relevance. This is page number 7.

Order by Relevance | Date

Total 363 results found since Jan 2013.

The Use of Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation Patients with History of Intra-Cranial Hemorrhage.
CONCLUSIONS: -Warfarin use may be beneficial for AF patients with prior ICH having a CHA2DS2-VASc score ≥6. Whether the use of non-vitamin K antagonist oral anticoagulants (NOACs) could lower the threshold for treatment deserves further study. PMID: 26969761 [PubMed - as supplied by publisher]
Source: Circulation - March 11, 2016 Category: Cardiology Authors: Chao TF, Liu CJ, Liao JN, Wang KL, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC, Chung FP, Chen TJ, Lip GY, Chen SA Tags: Circulation Source Type: research

Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation Health Services and Outcomes Research
Conclusions In patients with nonvalvular atrial fibrillation, apixaban was associated with lower risks of both stroke and major bleeding, dabigatran was associated with similar risk of stroke but lower risk of major bleeding, and rivaroxaban was associated with similar risks of both stroke and major bleeding in comparison to warfarin.
Source: JAHA:Journal of the American Heart Association - June 12, 2016 Category: Cardiology Authors: Yao, X., Abraham, N. S., Sangaralingham, L. R., Bellolio, M. F., McBane, R. D., Shah, N. D., Noseworthy, P. A. Tags: Atrial Fibrillation, Secondary Prevention, Anticoagulants, Transplantation, Cerebrovascular Disease/Stroke Health Services and Outcomes Research Source Type: research

Does early onset cataract increase the risk of ischemic stroke? A nationwide retrospective cohort study
This study was attempted to address the association between early onset cataract (EOC) and ischemic stroke. Using the Longitudinal Health Insurance Database 2000, we established an EOC cohort and a comparison cohort by using 4-fold propensity score matching according to age, gender and comorbidities to detect the incidence of ischemic stroke. A Cox model was used to express the risk of ischemic stroke for the EOC patients compared with the comparison cohort. After adjusting for age, gender and comorbidities of hypertension, diabetes mellitus, hyperlipidemia, coronary artery disease, asthma, chronic obstructive pulmonary...
Source: Internal and Emergency Medicine - December 21, 2016 Category: Emergency Medicine Source Type: research

Derivation and Validation of a Proposed Long Length of Stay (>= 7 days) Score in Patients Hospitalized for Acute Ischemic Stroke (P1.067)
Conclusions:Many factors play a role in determining the length of stay for AIS patients. Our study provides a scoring system that may help physicians predict which patients are more likely to have a prolonged hospital stay.Disclosure: Dr. Mahmood has nothing to disclose. Dr. Ali has nothing to disclose. Dr. Chauhan has nothing to disclose. Dr. Bianchi has nothing to disclose. Dr. Singhal has received personal compensation for activities with Medicolegal, ACTION Trial Stroke, Biogen, and Dock Technologies. Dr. Singhal holds stock and/or stock options in Biogen. Dr. Singhal has received research support from Boehringer Ingel...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Mahmood, S., Ali, S., Chauhan, M. A., Bianchi, N., Singhal, A., Schwamm, L. Tags: Practice, Policy, and Ethics I Source Type: research

Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Asian Patients With Atrial Fibrillation Clinical Sciences
Conclusions—In real-world practice among a high-risk Asian atrial fibrillation population, all 3 NOACs demonstrated similar risk of ischemic stroke and lower risk of ICH compared with warfarin. All-cause mortality was significantly lower only with dabigatran and apixaban.
Source: Stroke - October 23, 2017 Category: Neurology Authors: Myung-Jin Cha, Eue-Keun Choi, Kyung-Do Han, So-Ryoung Lee, Woo-Hyun Lim, Seil Oh, Gregory Y.H. Lip Tags: Atrial Fibrillation Original Contributions Source Type: research

Monotherapy of aspirin or warfarin for prevention of ischemic stroke in low-risk atrial fibrillation: A Easter Asian population-based study.
CONCLUSIONS: Warfarin is suggested to be prescribed in preventing ischemic stroke for low-stroke-risk atrial fibrillation patients with hypertension and hyperlipidemia. PMID: 29718533 [PubMed - as supplied by publisher]
Source: Cardiology Journal - May 2, 2018 Category: Cardiology Authors: Liu CY, Chen HC Tags: Cardiol J Source Type: research

Cost-Effectiveness of Rivaroxaban Compared to Warfarin for Stroke Prevention in Atrial Fibrillation.
CONCLUSIONS: Patients who had been treated with rivaroxaban may be a cost-effective alternative to warfarin for stroke prevention in Korean patients with AF. PMID: 30468041 [PubMed - as supplied by publisher]
Source: Korean Circulation Journal - November 25, 2018 Category: Cardiology Tags: Korean Circ J Source Type: research

Prevalence and Associated Stroke Risk of Human Immunodeficiency Virus-Infected Patients With Atrial Fibrillation 　- A Nationwide Cohort Study.
CONCLUSIONS: The risks of ischemic stroke/SE and major bleeding were significantly higher in HIV-infected patients compared with non-HIV-infected patients with AF. Despite this, the actual use of OACs among AF patients with HIV was suboptimal. PMID: 31619594 [PubMed - as supplied by publisher]
Source: Circulation Journal - October 16, 2019 Category: Cardiology Authors: Jung H, Yang PS, Jang E, Yu HT, Kim TH, Uhm JS, Kim JY, Sung JH, Pak HN, Lee MH, Lip GYH, Joung B Tags: Circ J Source Type: research

JAK2V617F Is a Risk Factor for TIA/Stroke in Young Patients
The objective of this study was to assess the risk of arterial thrombosis in patients who harbor the JAK2V617F allele burden ≥1% detected during workup for myeloproliferative neoplasms (MPNs). We conducted a large cross-sectional analysis consisted of 5,220 patients who were tested for JAK2V617F and 1,047,258 people matched in age from health care insurance provider, taking into account age, sex, hypertension, diabetes, atrial fibrillation. Compared with noncarriers, mutation carriers were older, less likely to be current or past smokers and had lower body mass index. There was no significant difference between the group...
Source: Thrombosis and Haemostasis - March 15, 2022 Category: Hematology Authors: Tamar Shapira Cohen Gabriel Chodick David M Steinberg Ehud Grossman Mordechai Shohat Ophira Salomon Source Type: research

Secondary stroke prevention in atrial fibrillation: a challenge in the clinical practice
Background: Despite clear evidence for the effectiveness of oral anticoagulation (OA) in patients with atrial fibrillation (AF), there is evidence for the underutilisation of this therapy in the secondary stroke prevention. We therefore investigate the link between the use of OA in stroke patients with AF and favourable clinical outcome following the acute event. Methods: The study population was determined by identifying the overlap of two different databases: a stroke registry and claims data of a health insurance company. Baseline data originated from the registry; documented dementia and the prescriptions for OA were d...
Source: BMC Neurology - September 30, 2014 Category: Neurology Authors: Christian TanislavSonja MildeSabine SchwartzkopffNicole SiewekeHeidrun KrämerMartin JuenemannBjörn MisselwitzManfred Kaps Source Type: research

Cost-Effectiveness Analysis of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation in Taiwan
ConclusionsApixaban was more cost effective than warfarin, dabigatran, and rivaroxaban for stroke prevention in patients with AF. Among the anticoagulant therapies, the WTP threshold of apixaban was about US$50,000 per QALY gained. These cost-effectiveness estimations provide useful information to aid clinical decision making in stroke prevention for AF patients.
Source: Clinical Drug Investigation - December 16, 2016 Category: Drugs & Pharmacology Source Type: research

Impact of medication adherence on risk of ischemic stroke, major bleeding, and deep vein thrombosis in atrial fibrillation patients using novel oral anticoagulants.
CONCLUSION: Adherence to NOACs for both 6 months and continued prolong use (up to 12-months) was associated with a reduction in IS and DVTPE risk, but did not substantially increase risk of MB. Further studies on newer, individual NOACs and older population are warranted. PMID: 29334815 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - January 18, 2018 Category: Research Tags: Curr Med Res Opin Source Type: research

Antithrombotic Treatment May Reduce Mortality Among New-Onset Atrial Fibrillation Patients with Gray-Zone Risk of Stroke.
This study aimed to evaluate whether gray zone AF patients could benefit from reduced all-cause mortality under antithrombotic treatment. This was a longitudinal cohort study performed using data from claim forms submitted to the Taiwan Bureau of National Health Insurance from January 2000 to December 2011. The new-onset AF patients consisted of a gray zone cohort with a total of 1237 patients being enrolled. The primary outcome was all-cause mortality between 2001 and 2011. Patients in the gray zone receiving antithrombotic treatment had a significant reduction in all-cause mortality [hazard ratio (HR): 0.21; 95% confiden...
Source: International Heart Journal - February 13, 2019 Category: Cardiology Tags: Int Heart J Source Type: research